|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.72 USD | -2.63% |
|
-7.29% | -7.01% |
| 06/11 | Tranche Update on TG Therapeutics, Inc.'s Equity Buyback Plan announced on September 3, 2025. | CI |
| 04/11 | TG Therapeutics, Inc. Raises Earnings Guidance for the Year 2025 | CI |
| Capitalization | 4.05B 3.47B 3.23B 3.01B 5.62B 365B 6.03B 37.18B 14.61B 175B 15.2B 14.89B 641B | P/E ratio 2025 * |
9.38x | P/E ratio 2026 * | 15.5x |
|---|---|---|---|---|---|
| Enterprise value | 3.75B 3.21B 2.99B 2.79B 5.2B 338B 5.58B 34.41B 13.53B 162B 14.07B 13.78B 593B | EV / Sales 2025 * |
6.19x | EV / Sales 2026 * | 3.8x |
| Free-Float |
90.42% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: TG Therapeutics, Inc.
| 1 day | -2.63% | ||
| 1 week | -7.29% | ||
| Current month | -7.01% | ||
| 1 month | -11.58% | ||
| 3 months | -17.89% | ||
| 6 months | -25.25% | ||
| Current year | -7.01% |
| 1 week | 27.35 |  | 30.9 |
| 1 month | 27.35 | | 31.85 |
| Current year | 27.35 | | 30.9 |
| 1 year | 25.28 | | 46.48 |
| 3 years | 6.46 | | 46.48 |
| 5 years | 3.48 | | 56.5 |
| 10 years | 3.32 | | 56.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 60 | 29/12/2011 |
Sean Power
DFI | Director of Finance/CFO | 44 | 29/12/2011 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 01/12/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CHM | Chairman | 60 | 29/12/2011 |
Laurence Charney
BRD | Director/Board Member | 79 | 01/03/2012 |
Yann Echelard
BRD | Director/Board Member | 62 | 09/11/2012 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.63% | -7.29% | -4.02% | +110.00% | 4.05B | |
| +1.64% | +3.79% | +35.14% | +201.01% | 968B | |
| +2.61% | +2.65% | +47.63% | +20.53% | 505B | |
| -0.02% | -0.06% | +25.62% | +44.55% | 389B | |
| -0.54% | +4.58% | +28.50% | +17.81% | 367B | |
| -0.76% | +4.62% | +29.39% | +22.31% | 295B | |
| -1.21% | +1.63% | +10.02% | -2.31% | 271B | |
| -0.10% | +4.85% | +25.30% | +35.24% | 274B | |
| +1.66% | +11.12% | -37.16% | -15.66% | 263B | |
| -0.17% | +1.50% | +24.14% | +20.16% | 175B | |
| Average | -0.06% | +2.72% | +18.46% | +45.36% | 351.22B | |
| Weighted average by Cap. | +0.25% | +3.70% | +25.98% | +69.55% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 606M 519M 483M 450M 841M 54.62B 902M 5.56B 2.19B 26.13B 2.27B 2.23B 95.81B | 896M 767M 713M 665M 1.24B 80.72B 1.33B 8.22B 3.23B 38.62B 3.36B 3.29B 142B |
| Net income | 480M 411M 382M 356M 665M 43.23B 714M 4.4B 1.73B 20.68B 1.8B 1.76B 75.83B | 293M 251M 233M 217M 406M 26.39B 436M 2.69B 1.06B 12.62B 1.1B 1.08B 46.29B |
| Net Debt | -301M -258M -240M -224M -418M -27.16B -448M -2.76B -1.09B -12.99B -1.13B -1.11B -47.64B | -645M -553M -514M -479M -895M -58.16B -960M -5.92B -2.33B -27.83B -2.42B -2.37B -102B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/01/26 | 27.72 $ | -2.63% | 2,834,030 |
| 09/01/26 | 28.47 $ | -6.66% | 3,255,187 |
| 08/01/26 | 30.50 $ | +0.53% | 2,313,455 |
| 07/01/26 | 30.34 $ | +3.16% | 2,174,550 |
| 06/01/26 | 29.41 $ | -1.64% | 2,857,991 |
Delayed Quote Nasdaq, 13 January 2026 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TGTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition